title: Dysmenorrhea treatment with a single daily dose of rofecoxib.
abstract: OBJECTIVE
  To investigate the efficacy of single daily doses of rofecoxib, a selective inhibitor of cyclooxygenase-2, in dysmenorrhea.
  
  
  METHODS
  Fifty-five patients were included in this randomized, placebo-controlled, cross-over study. Patients were randomized to use placebo, naproxen sodium (550 mg), 25 and 50 mg doses of rofecoxib in various orders. Pain intensity, analgesic efficacy of drugs, total number of pills used and side effects were evaluated.
  
  
  RESULTS
  Rofecoxib with daily single doses of 25 and 50 mg decreased the pain intensity in a manner similar to naproxen sodium. Most of the patients (85.45% and 96.46%) evaluated the analgesic efficacy of rofecoxib as 'perfectly effective'. Rofecoxib was found to be effective for pain relief both in primary and secondary dysmenorrhea. Gastrointestinal adverse effects were less than those with naproxen sodium.
  
  
  CONCLUSIONS
  A 'one a day' dose of 25 mg rofecoxib is an effective choice with lower gastrointestinal adverse effects than naproxen sodium.
authors.affiliation: Ankara Numune Education and Research Hospital, Division of Gynecology and Obstetrics, Ankara, Turkey. izzet.sahin@superonline.com
authors.forename: I
authors.initials: I
authors.lastname: Sahin
authors.forename: F
authors.initials: F
authors.lastname: Saraçoğlu
authors.forename: Y
authors.initials: Y
authors.lastname: Kurban
authors.forename: B
authors.initials: B
authors.lastname: Türkkani
mesh_terms: D000284:Administration, Oral; D000328:Adult; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D018592:Cross-Over Studies; D016861:Cyclooxygenase Inhibitors / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D004334:Drug Administration Schedule; D004412:Dysmenorrhea / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007783:Lactones / Q000008:administration & dosage*; D009288:Naproxen / Q000008:administration & dosage*; D010147:Pain Measurement; D017060:Patient Satisfaction; D011336:Probability; D018570:Risk Assessment; D012720:Severity of Illness Index; D013450:Sulfones; D016896:Treatment Outcome
chemical_list: D016861:Cyclooxygenase Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib; D009288:Naproxen